Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1984 May;44(2):344–350. doi: 10.1128/iai.44.2.344-350.1984

Two adjuvant-active muramyl dipeptide analogs induce differential production of lymphocyte-activating factor and a factor causing distress in guinea pigs.

N E Byars
PMCID: PMC263524  PMID: 6609127

Abstract

Many adjuvant-active analogs of muramyl dipeptide (MDP) have been described. Unfortunately, most have been found to induce pyrexia or other adverse side effects in several species. In the guinea pig, these side effects include the guinea pig distress syndrome, which lasts 24 to 48 h, and enhancement of endotoxin shock. A dose-related response to MDP or N-acetylmuramyl-L-alpha-aminobutyryl-D-isoglutamine [( Abu1]-MDP) was observed. However, we found several adjuvant-active analogs which were completely innocuous in guinea pigs. 2-(2-Acetamido-2-deoxy-D-glucose-3-O-yl)-D-hexanoyl-L-alanyl-D-isoglutam ine (3'-n-propyl-MDP) was one such compound. To understand the differences between the toxic and nontoxic compounds, macrophage stimulation in vitro was studied. Both compounds stimulated guinea pig peritoneal macrophages to produce lymphocyte-activating factor in vitro. However, the supernatant from 3'-n-propyl-MDP-stimulated macrophages had no observable effects on guinea pigs, whereas the dialyzed supernatant from [Abu1]-MDP-stimulated cells readily induced the guinea pig distress syndrome. Sephadex G-150 chromatography showed that both analogs stimulated production of a major (60,000) and minor (11,000) peak of lymphocyte-activating factor activity. The factor causing the guinea pig distress syndrome was found only in the low-molecular-weight fraction of [Abu1]-MDP-treated cell supernatants. Thus, one difference between the nontoxic and toxic compounds is their ability to produce lymphocyte-activating factor in the absence of the toxic factor. The lack of toxicity of 3'-n-propyl-MDP makes it an attractive compound for use in vaccines.

Full text

PDF
344

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chang Y. H., Pearson C. M., Chedid L. Adjuvant polyarthritis. V. Induction by N-acetylmuramyl-L-alanyl-D-isoglutamine, the smallest peptide subunit of bacterial peptidoglycan. J Exp Med. 1981 Apr 1;153(4):1021–1026. doi: 10.1084/jem.153.4.1021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Damais C., Riveau G., Parant M., Gerota J., Chedid L. Production of lymphocyte activating factor in the absence of endogenous pyrogen by rabbit or human leukocytes stimulated by a muramyl dipeptide derivative. Int J Immunopharmacol. 1982;4(5):451–462. doi: 10.1016/0192-0561(82)90020-0. [DOI] [PubMed] [Google Scholar]
  3. Dinarello C. A., Elin R. J., Chedid L., Wolff S. M. The pyrogenicity of the synthetic adjuvant muramyl dipeptide and two structural analogues. J Infect Dis. 1978 Dec;138(6):760–767. doi: 10.1093/infdis/138.6.760. [DOI] [PubMed] [Google Scholar]
  4. Ellouz F., Adam A., Ciorbaru R., Lederer E. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem Biophys Res Commun. 1974 Aug 19;59(4):1317–1325. doi: 10.1016/0006-291x(74)90458-6. [DOI] [PubMed] [Google Scholar]
  5. Hamamoto Y., Kobara Y., Kojima A., Kumazawa Y., Yasuhira K. Experimental production of pulmonary granulomas. I. Immune granulomas induced by chemically modified cell walls and their constituents. Br J Exp Pathol. 1981 Jun;62(3):259–269. [PMC free article] [PubMed] [Google Scholar]
  6. Iribe H., Koga T., Onoue K., Kotani S., Kusumoto S., Shiba T. Macrophage-stimulating effect of a synthetic muramyl dipeptide and its adjuvant-active and -inactive analogs for the production of T-cell activating monokines. Cell Immunol. 1981 Oct;64(1):73–83. doi: 10.1016/0008-8749(81)90459-7. [DOI] [PubMed] [Google Scholar]
  7. Iribe H., Koga T., Onoue K. Production of T cell-activating monokine of guinea pig macrophages induced by MDP and partial characterization of the monokine. J Immunol. 1982 Sep;129(3):1029–1032. [PubMed] [Google Scholar]
  8. Kohashi O., Tanaka A., Kotani S., Shiba T., Kusumoto S., Yokogawa K., Kawata S., Ozawa A. Arthritis-inducing ability of a synthetic adjuvant, N-acetylmuramyl peptides, and bacterial disaccharide peptides related to different oil vehicles and their composition. Infect Immun. 1980 Jul;29(1):70–75. doi: 10.1128/iai.29.1.70-75.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kotani S., Watanabe Y., Shimono T., Harada K., Shiba T. Correlation between the immunoadjuvant activities and pyrogenicities of synthetic N-acetylmuramyl-peptides or -amino acids. Biken J. 1976 Mar;19(1):9–13. [PubMed] [Google Scholar]
  10. Krueger J. M., Pappenheimer J. R., Karnovsky M. L. Sleep-promoting effects of muramyl peptides. Proc Natl Acad Sci U S A. 1982 Oct;79(19):6102–6106. doi: 10.1073/pnas.79.19.6102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Lefrancier P., Derrien M., Jamet X., Choay J., Lederer E., Audibert F., Parant M., Parant F., Chedid L. Apyrogenic, adjuvant-active N-acetylmuramyl-dipeptides. J Med Chem. 1982 Jan;25(1):87–90. doi: 10.1021/jm00343a018. [DOI] [PubMed] [Google Scholar]
  12. Mizel S. B., Mizel D. Purification to apparent homogeneity of murine interleukin 1. J Immunol. 1981 Mar;126(3):834–837. [PubMed] [Google Scholar]
  13. Murphy P. A., Simon P. L., Willoughby W. F. Endogenous pyrogens made by rabbit peritoneal exudate cells are identical with lymphocyte-activating factors made by rabbit alveolar macrophages. J Immunol. 1980 May;124(5):2498–2501. [PubMed] [Google Scholar]
  14. Nagao S., Tanaka A. Muramyl dipeptide-induced adjuvant arthritis. Infect Immun. 1980 May;28(2):624–626. doi: 10.1128/iai.28.2.624-626.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Oppenheim J. J., Togawa A., Chedid L., Mizel S. Components of mycobacteria and muramyl dipeptide with adjuvant activity induce lymphocyte activating factor. Cell Immunol. 1980 Mar 1;50(1):71–81. doi: 10.1016/0008-8749(80)90007-6. [DOI] [PubMed] [Google Scholar]
  16. Pabst M. J., Johnston R. B., Jr Increased production of superoxide anion by macrophages exposed in vitro to muramyl dipeptide or lipopolysaccharide. J Exp Med. 1980 Jan 1;151(1):101–114. doi: 10.1084/jem.151.1.101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Parant M., Parant F., Chedid L., Yapo A., Petit J. F., Lederer E. Fate of the synthetic immunoadjuvant, muramyl dipeptide (14C-labelled) in the mouse. Int J Immunopharmacol. 1979;1(1):35–41. doi: 10.1016/0192-0561(79)90028-6. [DOI] [PubMed] [Google Scholar]
  18. Parant M., Riveau G., Parant F., Dinarello C. A., Wolff S. M., Chedid L. Effect of indomethacin on increased resistance to bacterial infection and on febrile responses induced by muramyl dipeptide. J Infect Dis. 1980 Nov;142(5):708–715. doi: 10.1093/infdis/142.5.708. [DOI] [PubMed] [Google Scholar]
  19. Ribi E. E., Cantrell J. L., Von Eschen K. B., Schwartzman S. M. Enhancement of endotoxic shock by N-acetylmuramyl-L-alanyl-(L-seryl)-D-isoglutamine (muramyl dipeptide). Cancer Res. 1979 Nov;39(11):4756–4759. [PubMed] [Google Scholar]
  20. Riveau G., Masek K., Parant M., Chedid L. Central pyrogenic activity of muramyl dipeptide. J Exp Med. 1980 Oct 1;152(4):869–877. doi: 10.1084/jem.152.4.869. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. STAVITSKY A. B. Micromethods for the study of proteins and antibodies. I. Procedure and general applications of hemagglutination and hemagglutination-inhibition reactions with tannic acid and protein-treated red blood cells. J Immunol. 1954 May;72(5):360–367. [PubMed] [Google Scholar]
  22. TABACHNICK M., SOBOTKA H. Azoproteins. I. Spectrophotometric studies of amino acid azo derivatives. J Biol Chem. 1959 Jul;234(7):1726–1730. [PubMed] [Google Scholar]
  23. TABACHNICK M., SOBOTKA H. Azoproteins. II. A spectrophotometric study of the coupling of diazotized arsanilic acid with proteins. J Biol Chem. 1960 Apr;235:1051–1054. [PubMed] [Google Scholar]
  24. Tenu J. P., Lederer E., Petit J. F. Stimulation of thymocyte mitogenic protein secretion and of cytostatic activity of mouse peritoneal macrophages by trehalose dimycolate and muramyldipeptide. Eur J Immunol. 1980 Aug;10(8):647–653. doi: 10.1002/eji.1830100813. [DOI] [PubMed] [Google Scholar]
  25. Wahl S. M., Wahl L. M., McCarthy J. B., Chedid L., Mergenhagen S. E. Macrophage activation by mycobacterial water soluble compounds and synthetic muramyl dipeptide. J Immunol. 1979 Jun;122(6):2226–2231. [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES